TY - JOUR
T1 - Chronoecological health watch of arterial stiffness and neuro-cardio-pulmonary function in elderly community at high altitude (3524 m), compared with Japanese town
AU - Otsuka, K.
AU - Norboo, T.
AU - Otsuka, Y.
AU - Higuchi, H.
AU - Hayajiri, M.
AU - Narushima, C.
AU - Sato, Y.
AU - Tsugoshi, T.
AU - Murakami, S.
AU - Wada, T.
AU - Ishine, M.
AU - Okumiya, K.
AU - Matsubayashi, K.
AU - Yano, S.
AU - Chogyal, T.
AU - Angchuk, D.
AU - Ichihara, K.
AU - Cornelissen-Guillaume, Germaine G
AU - Halberg, F.
N1 - Funding Information:
This study was supported by Fukuda Medical Foundation (Grant in 2004 for the study on association between arterial stiffness and cognitive impairment in community-dwelling subjects over 70 years old).
PY - 2005/10
Y1 - 2005/10
N2 - Effects of high altitude on arterial stiffness and neuro-cardio-pulmonary function were studied. Blood pressure (BP) and heart rate (HR) were measured in a sitting position on resting Ladakhis, living at an altitude of 3250-4647 m (Phey village, 3250 m: 17 men and 55 women; Chumathang village, 4193 m: 29 men and 47 women; Sumdo village, 4540 m: 38 men and 57 women; and Korzok village, 4647 m: 84 men and 70 women). The neuro-cardio-pulmonary function, including the Kohs block design test, the Up and Go, the Functional Reach and the Button tests, was examined in 40 elderly subjects (19 men and 21 women, mean age: 74.7 ± 3.3 years) in Leh, Ladakh (altitude: 3524 m), for comparison with 324 elderly citizens (97 men and 227 women, mean age: 80.7 ± 4.7 years) of Tosa, Japan (altitude: 250 m). Cardio-Ankle Vascular Index (CAVI) was measured as the heart-ankle pulse wave velocity (PWV) in these subjects using a VaSera CAVI instrument (Fukuda Denshi, Tokyo). SpO2 decreased while Hb and diastolic BP increased with increasing altitude. At higher altitude, residents were younger and leaner. Women in Leh vs. Tosa had a poorer cognitive function, estimated by the Kohs block design test (3.7 ± 3.6 vs. 16.4 ± 9.6 points, P < 0.0001) and poorer ADL functions (Functional Reach: 13.7 ± 7.0 cm vs. 25.3 ± 8.7 cm, P < 0.0001; Button test: 22.5 ± 4.8 vs. 14.8 ± 5.7 s, P < 0.0001). Time estimation was shorter at high altitude (60-s estimation with counting: 41.1% shorter in men and 23.0% shorter in women). A higher voltage of the QRS complex was observed in the ECG of Leh residents, but two times measurement of CAVI showed no statistically significant differences between Leh and Tosa (two times of CAVI measures; 9.49 vs. 10.01 m/s and 9.41 vs. 10.05 m/s, respectively), suggesting that most residents succeed to adapt sufficiently to the high-altitude environment. However, correlation of CAVI with age shows several cases who show an extreme increase in CAVI. Thus, for the prevention of stroke and other adverse cardiovascular outcomes, including dementia, CAVI may be very useful, especially at high altitude. In conclusion, elderly people living at high altitude have a higher risk of cardiovascular disease than low-latitude peers. To determine how these indices are associated with maintained cognitive function deserves further study by the longitudinal follow-up of these communities in terms of longevity and aging in relation to their neuro-cardio-pulmonary function.
AB - Effects of high altitude on arterial stiffness and neuro-cardio-pulmonary function were studied. Blood pressure (BP) and heart rate (HR) were measured in a sitting position on resting Ladakhis, living at an altitude of 3250-4647 m (Phey village, 3250 m: 17 men and 55 women; Chumathang village, 4193 m: 29 men and 47 women; Sumdo village, 4540 m: 38 men and 57 women; and Korzok village, 4647 m: 84 men and 70 women). The neuro-cardio-pulmonary function, including the Kohs block design test, the Up and Go, the Functional Reach and the Button tests, was examined in 40 elderly subjects (19 men and 21 women, mean age: 74.7 ± 3.3 years) in Leh, Ladakh (altitude: 3524 m), for comparison with 324 elderly citizens (97 men and 227 women, mean age: 80.7 ± 4.7 years) of Tosa, Japan (altitude: 250 m). Cardio-Ankle Vascular Index (CAVI) was measured as the heart-ankle pulse wave velocity (PWV) in these subjects using a VaSera CAVI instrument (Fukuda Denshi, Tokyo). SpO2 decreased while Hb and diastolic BP increased with increasing altitude. At higher altitude, residents were younger and leaner. Women in Leh vs. Tosa had a poorer cognitive function, estimated by the Kohs block design test (3.7 ± 3.6 vs. 16.4 ± 9.6 points, P < 0.0001) and poorer ADL functions (Functional Reach: 13.7 ± 7.0 cm vs. 25.3 ± 8.7 cm, P < 0.0001; Button test: 22.5 ± 4.8 vs. 14.8 ± 5.7 s, P < 0.0001). Time estimation was shorter at high altitude (60-s estimation with counting: 41.1% shorter in men and 23.0% shorter in women). A higher voltage of the QRS complex was observed in the ECG of Leh residents, but two times measurement of CAVI showed no statistically significant differences between Leh and Tosa (two times of CAVI measures; 9.49 vs. 10.01 m/s and 9.41 vs. 10.05 m/s, respectively), suggesting that most residents succeed to adapt sufficiently to the high-altitude environment. However, correlation of CAVI with age shows several cases who show an extreme increase in CAVI. Thus, for the prevention of stroke and other adverse cardiovascular outcomes, including dementia, CAVI may be very useful, especially at high altitude. In conclusion, elderly people living at high altitude have a higher risk of cardiovascular disease than low-latitude peers. To determine how these indices are associated with maintained cognitive function deserves further study by the longitudinal follow-up of these communities in terms of longevity and aging in relation to their neuro-cardio-pulmonary function.
KW - ADL function
KW - Arterial stiffness
KW - Cardio-ankle vascular index
KW - Cognitive function
KW - Elderly community-dwelling people
KW - Gender difference
KW - High-altitude
KW - Time estimation
UR - http://www.scopus.com/inward/record.url?scp=27744607521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744607521&partnerID=8YFLogxK
U2 - 10.1016/S0753-3322(05)80012-5
DO - 10.1016/S0753-3322(05)80012-5
M3 - Article
C2 - 16275510
AN - SCOPUS:27744607521
SN - 0753-3322
VL - 59
SP - S58-S67
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
IS - SUPPL. 1
ER -